{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T04:02:04Z","timestamp":1785124924842,"version":"3.55.0"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"The Qinghai Key Construction Project of Specialized Departments of Qinghai University Affiliated Hospital"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-026-03331-5","type":"journal-article","created":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T06:30:13Z","timestamp":1783060213000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Nanomedicine-based sensitization and resistance reversal in immunotherapy of clear cell renal cell carcinoma: from tumor microenvironment to precision delivery"],"prefix":"10.1007","volume":"43","author":[{"given":"Jinhu","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyang","family":"Qiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhao","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Mi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhangjie","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guojun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,3]]},"reference":[{"issue":"1","key":"3331_CR1","doi-asserted-by":"publisher","first-page":"17009","DOI":"10.1038\/nrdp.2017.9","volume":"3","author":"JJ Hsieh","year":"2017","unstructured":"Hsieh JJ, Purdue MP, Signoretti S, Swanton C, Albiges L, Schmidinger M, et al. Renal cell carcinoma. Nat Rev Dis Primers. 2017;3(1):17009.","journal-title":"Nat Rev Dis Primers"},{"issue":"4","key":"3331_CR2","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1056\/NEJMra1601333","volume":"376","author":"TK Choueiri","year":"2017","unstructured":"Choueiri TK, Motzer RJ. Systemic Therapy for Metastatic Renal-Cell Carcinoma. N Engl J Med. 2017;376(4):354\u201366.","journal-title":"N Engl J Med"},{"issue":"1","key":"3331_CR3","doi-asserted-by":"publisher","first-page":"4","DOI":"10.6004\/jnccn.2024.0008","volume":"22","author":"RJ Motzer","year":"2024","unstructured":"Motzer RJ, Jonasch E, Agarwal N, Alva A, Bagshaw H, Baine M, et al. NCCN Guidelines\u00ae Insights: Kidney Cancer, Version 2.2024. J Natl Compr Canc Netw. 2024;22(1):4\u201316.","journal-title":"J Natl Compr Canc Netw"},{"issue":"4","key":"3331_CR4","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/s41571-020-00455-z","volume":"18","author":"DA Braun","year":"2021","unstructured":"Braun DA, Bakouny Z, Hirsch L, Flippot R, Van Allen EM, Wu CJ, et al. Beyond conventional immune-checkpoint inhibition - novel immunotherapies for renal cell carcinoma. Nat Rev Clin Oncol. 2021;18(4):199\u2013214.","journal-title":"Nat Rev Clin Oncol"},{"issue":"5","key":"3331_CR5","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/S1470-2045(22)00128-0","volume":"23","author":"YA Vano","year":"2022","unstructured":"Vano YA, Elaidi R, Bennamoun M, Chevreau C, Borchiellini D, Pannier D, et al. Nivolumab, nivolumab-ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial. Lancet Oncol. 2022;23(5):612\u201324.","journal-title":"Lancet Oncol"},{"issue":"10","key":"3331_CR6","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1158\/2159-8290.CD-19-0499","volume":"9","author":"L Vuong","year":"2019","unstructured":"Vuong L, Kotecha RR, Voss MH, Hakimi AA. Tumor Microenvironment Dynamics in Clear-Cell Renal Cell Carcinoma. Cancer Discov. 2019;9(10):1349\u201357.","journal-title":"Cancer Discov"},{"issue":"6","key":"3331_CR7","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1038\/s41578-019-0108-1","volume":"4","author":"J Nam","year":"2019","unstructured":"Nam J, Son S, Park KS, Zou W, Shea LD, Moon JJ. Cancer nanomedicine for combination cancer immunotherapy. Nat Reviews Mater. 2019;4(6):398\u2013414.","journal-title":"Nat Reviews Mater"},{"issue":"2","key":"3331_CR8","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41573-020-0090-8","volume":"20","author":"MJ Mitchell","year":"2021","unstructured":"Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME, Peppas NA, Langer R. Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov. 2021;20(2):101\u201324.","journal-title":"Nat Rev Drug Discov"},{"key":"3331_CR9","doi-asserted-by":"crossref","unstructured":"Shi Y, Lammers T. Combining Nanomedicine and Immunotherapy. Acc Chem Res.2019;52(6):1543\u201354.","DOI":"10.1021\/acs.accounts.9b00148"},{"key":"3331_CR10","doi-asserted-by":"crossref","unstructured":"Pan Y, Wu X, Liu L, Zhao C, Zhang J, Yang S et al. Genetically Engineered Cytomembrane Nanovaccines for Cancer Immunother apy. Adv Healthcare Materials.13(13).","DOI":"10.1002\/adhm.202400068"},{"key":"3331_CR11","doi-asserted-by":"crossref","unstructured":"Pan Y, Yu L, Liu L, Zhang J, Liang S, Parshad B et al. Genetically engineered nanomodulators elicit potent immunity against c ancer stem cells by checkpoint blockade and hypoxia relief. Bioact Mater. 2024;38:31-44.","DOI":"10.1016\/j.bioactmat.2024.04.008"},{"key":"3331_CR12","doi-asserted-by":"crossref","unstructured":"Liao Y, Zhao C, Pan Y, Guo Y, Liu L, Wu J et al. Genetically engineered cellular nanoparticles loaded with curcuminoids for cancer immunotherapy. Theranostics. 2024;14(16):6409-25.","DOI":"10.7150\/thno.99033"},{"key":"3331_CR13","doi-asserted-by":"publisher","first-page":"684050","DOI":"10.3389\/fmolb.2021.684050","volume":"8","author":"W Zhong","year":"2021","unstructured":"Zhong W, Zhong H, Zhang F, Huang C, Lin Y, Huang J. Characterization of Hypoxia-Related Molecular Subtypes in Clear Cell Renal Cell Carcinoma to Aid Immunotherapy and Targeted Therapy via Multi-Omics Analysis. Front Mol Biosci. 2021;8:684050.","journal-title":"Front Mol Biosci"},{"issue":"7","key":"3331_CR14","doi-asserted-by":"publisher","first-page":"112736","DOI":"10.1016\/j.celrep.2023.112736","volume":"42","author":"M Tabata","year":"2023","unstructured":"Tabata M, Sato Y, Kogure Y, McClure MB, Oshikawa-Kumade Y, Saito Y, et al. Inter- and intra-tumor heterogeneity of genetic and immune profiles in inherited renal cell carcinoma. Cell Rep. 2023;42(7):112736.","journal-title":"Cell Rep"},{"key":"3331_CR15","doi-asserted-by":"crossref","unstructured":"Wang B, Zhao Q, Zhang Y, Liu Z, Zheng Z, Liu S et al. Targeting hypoxia in the tumor microenvironment: a potential strategy to improve cancer immunotherapy. J Exp Clin Cancer Res. 2021;40(1).","DOI":"10.1186\/s13046-020-01820-7"},{"issue":"8","key":"3331_CR16","doi-asserted-by":"publisher","first-page":"4854","DOI":"10.1111\/jcmm.14356","volume":"23","author":"J Zhou","year":"2019","unstructured":"Zhou J, Wang G, Chen Y, Wang H, Hua Y, Cai Z. Immunogenic cell death in cancer therapy: Present and emerging inducers. J Cell Mol Med. 2019;23(8):4854\u201365.","journal-title":"J Cell Mol Med"},{"key":"3331_CR17","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/j.jcis.2024.07.113","volume":"675","author":"X Liu","year":"2024","unstructured":"Liu X, Wang X, Zang D, Chang Y, Su W, Li G, et al. pH-responsive oxygen self-sufficient smart nanoplatform for enhanced tumor chemotherapy and photodynamic therapy. J Colloid Interface Sci. 2024;675:1080\u201390.","journal-title":"J Colloid Interface Sci"},{"key":"3331_CR18","doi-asserted-by":"crossref","unstructured":"Gong F, Yang N, Wang X, Zhao Q, Chen Q, Liu Z et al. Tumor microenvironment-responsive intelligent nanoplatforms for cancer theranostics. Nano Today, 2020;32: 100851.","DOI":"10.1016\/j.nantod.2020.100851"},{"issue":"1","key":"3331_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41423-019-0306-1","volume":"17","author":"K Nakamura","year":"2020","unstructured":"Nakamura K, Smyth MJ. Myeloid immunosuppression and immune checkpoints in the tumor microenvironment. Cell Mol Immunol. 2020;17(1):1\u201312.","journal-title":"Cell Mol Immunol"},{"issue":"1","key":"3331_CR20","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s12951-020-00589-3","volume":"18","author":"L Pinton","year":"2020","unstructured":"Pinton L, Magri S, Masetto E, Vettore M, Schibuola I, Ingangi V, et al. Targeting of immunosuppressive myeloid cells from glioblastoma patients by modulation of size and surface charge of lipid nanocapsules. J Nanobiotechnol. 2020;18(1):31.","journal-title":"J Nanobiotechnol"},{"issue":"2","key":"3331_CR21","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1158\/1078-0432.CCR-20-1610","volume":"27","author":"DH Aggen","year":"2021","unstructured":"Aggen DH, Ager CR, Obradovic AZ, Chowdhury N, Ghasemzadeh A, Mao W, et al. Blocking IL1 Beta Promotes Tumor Regression and Remodeling of the Myeloid Compartment in a Renal Cell Carcinoma Model: Multidimensional Analyses. Clin Cancer Res. 2021;27(2):608\u201321.","journal-title":"Clin Cancer Res"},{"key":"3331_CR22","first-page":"24","volume":"118","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Narayanan SP, Mannan R, Raskind G, Wang X, Vats P, et al. Single-cell analyses of renal cell cancers reveal insights into tumor microenvironment, cell of origin, and therapy response. Proc Natl Acad Sci U S A. 2021;118:24.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"3331_CR23","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1158\/1078-0432.CCR-20-3084","volume":"27","author":"M Ficial","year":"2021","unstructured":"Ficial M, Jegede OA, Sant\u2019Angelo M, Hou Y, Flaifel A, Pignon JC, et al. Expression of T-Cell Exhaustion Molecules and Human Endogenous Retroviruses as Predictive Biomarkers for Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma. Clin Cancer Res. 2021;27(5):1371\u201380.","journal-title":"Clin Cancer Res"},{"issue":"11","key":"3331_CR24","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1016\/j.apsb.2020.08.010","volume":"10","author":"Y Zhu","year":"2020","unstructured":"Zhu Y, Yu X, Thamphiwatana SD, Zheng Y, Pang Z. Nanomedicines modulating tumor immunosuppressive cells to enhance cancer immunotherapy. Acta Pharm Sin B. 2020;10(11):2054\u201374.","journal-title":"Acta Pharm Sin B"},{"issue":"1","key":"3331_CR25","first-page":"92","volume":"5","author":"NT Trac","year":"2020","unstructured":"Trac NT, Chung EJ. Peptide-based targeting of immunosuppressive cells in cancer. Bioact Mater. 2020;5(1):92\u2013101.","journal-title":"Bioact Mater"},{"key":"3331_CR26","doi-asserted-by":"publisher","first-page":"111378","DOI":"10.1016\/j.colsurfb.2020.111378","volume":"197","author":"M Pei","year":"2021","unstructured":"Pei M, Xu R, Zhang C, Wang X, Li C, Hu Y. Mannose-functionalized antigen nanoparticles for targeted dendritic cells, accelerated endosomal escape and enhanced MHC-I antigen presentation. Colloids Surf B Biointerfaces. 2021;197:111378.","journal-title":"Colloids Surf B Biointerfaces"},{"key":"3331_CR27","doi-asserted-by":"crossref","unstructured":"Yan W, Li Y, Zou Y, Zhu R, Wu T, Sun X et al. Breaking Tumor Immunosuppressive Network by Regulating Multiple Nodes with Triadic Drug Delivery Nanoparticles. ACS Nano. 2023;17(18):17826-44.","DOI":"10.1021\/acsnano.3c03387"},{"key":"3331_CR28","doi-asserted-by":"publisher","first-page":"120609","DOI":"10.1016\/j.biomaterials.2020.120609","volume":"269","author":"H Wang","year":"2021","unstructured":"Wang H, Li J, Wang Z, Wang Y, Xu X, Gong X, et al. Tumor-permeated bioinspired theranostic nanovehicle remodels tumor immunosuppression for cancer therapy. Biomaterials. 2021;269:120609.","journal-title":"Biomaterials"},{"key":"3331_CR29","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.biomaterials.2018.02.034","volume":"164","author":"H Kim","year":"2018","unstructured":"Kim H, Niu L, Larson P, Kucaba TA, Murphy KA, James BR, et al. Polymeric nanoparticles encapsulating novel TLR7\/8 agonists as immunostimulatory adjuvants for enhanced cancer immunotherapy. Biomaterials. 2018;164:38\u201353.","journal-title":"Biomaterials"},{"key":"3331_CR30","doi-asserted-by":"publisher","first-page":"610533","DOI":"10.3389\/fmolb.2020.610533","volume":"7","author":"RG Thomas","year":"2020","unstructured":"Thomas RG, Surendran SP, Jeong YY. Tumor Microenvironment-Stimuli Responsive Nanoparticles for Anticancer Therapy. Front Mol Biosci. 2020;7:610533.","journal-title":"Front Mol Biosci"},{"key":"3331_CR31","doi-asserted-by":"crossref","unstructured":"Feng X, Zhu H, Shen J, Wang Y, Liu S, Chen X et al. Improved Hypoxic Microenvironment By Nanoformulation For Effective T C ell Therapy In Mice Model. Int J Nanomed. 2025;20:10073-87.","DOI":"10.2147\/IJN.S522504"},{"key":"3331_CR32","doi-asserted-by":"crossref","unstructured":"Zhou M, Xie Y, Xu S, Xin J, Wang J, Han T et al. Hypoxia-activated nanomedicines for effective cancer therapy. Eur J Med Chem. 2020;195:112274.","DOI":"10.1016\/j.ejmech.2020.112274"},{"issue":"40","key":"3331_CR33","doi-asserted-by":"publisher","first-page":"9351","DOI":"10.1039\/D0TB01692F","volume":"8","author":"BA Ma","year":"2020","unstructured":"Ma BA, Sun CY. Tumor pH-triggered charge conversion nanocarriers with on-demand drug release for precise cancer therapy. J Mater Chem B. 2020;8(40):9351\u201361.","journal-title":"J Mater Chem B"},{"issue":"1","key":"3331_CR34","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1186\/s12951-023-02240-3","volume":"21","author":"C Wang","year":"2023","unstructured":"Wang C, Xu Y-H, Xu H-Z, Li K, Zhang Q, Shi L, et al. PD-L1 blockade TAM-dependently potentiates mild photothermal therapy against triple-negative breast cancer. J Nanobiotechnol. 2023;21(1):476.","journal-title":"J Nanobiotechnol"},{"key":"3331_CR35","doi-asserted-by":"crossref","unstructured":"Grillone A, Riva ER, Mondini A, Forte C, Calucci L, Innocenti C et al. Active Targeting of Sorafenib: Preparation, Characterization, and In V itro Testing of Drug-Loaded Magnetic Solid Lipid Nanoparticles. Adv Healthc Mater. 2015;4(11):1681-90.","DOI":"10.1002\/adhm.201500235"},{"issue":"8","key":"3331_CR36","doi-asserted-by":"publisher","first-page":"3562","DOI":"10.7150\/thno.39944","volume":"10","author":"L Chen","year":"2020","unstructured":"Chen L, Wang Z, Xu Q, Liu Y, Chen L, Guo S, et al. The failure of DAC to induce OCT2 expression and its remission by hemoglobin-based nanocarriers under hypoxia in renal cell carcinoma. Theranostics. 2020;10(8):3562\u201378.","journal-title":"Theranostics"},{"key":"3331_CR37","doi-asserted-by":"crossref","unstructured":"Morais M, Machado V, Figueiredo P, Dias F, Craveiro R, Lencart J et al. Silver Nanoparticles (AgNPs) as Enhancers of Everolimus and Radiothera py Sensitivity on Clear Cell Renal Cell Carcinoma. Antioxidants.12(12):2051.","DOI":"10.3390\/antiox12122051"},{"issue":"1","key":"3331_CR38","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/s41467-024-55529-8","volume":"16","author":"J Yu","year":"2025","unstructured":"Yu J, Wu J, Huang J, Xu C, Xu M, Koh CZH, et al. Hypoxia-tolerant polymeric photosensitizer prodrug for cancer photo-immunotherapy. Nat Commun. 2025;16(1):153.","journal-title":"Nat Commun"},{"issue":"10","key":"3331_CR39","doi-asserted-by":"publisher","first-page":"e441","DOI":"10.1038\/am.2017.185","volume":"9","author":"L Zhang","year":"2017","unstructured":"Zhang L, Wang P, Feng Q, Wang N, Chen Z, Huang Y, et al. Lipid nanoparticle-mediated efficient delivery of CRISPR\/Cas9 for tumor therapy. NPG Asia Mater. 2017;9(10):e441\u2013e.","journal-title":"NPG Asia Mater"},{"key":"3331_CR40","doi-asserted-by":"crossref","unstructured":"Pisani A, Donno R, Gennari A, Cibecchini G, Catalano F, Marotta R et al. CXCL12-PLGA\/Pluronic Nanoparticle Internalization Abrogates CXCR4-Mediated Cell Migration. Nanomaterials. 2020;10(11):2304.","DOI":"10.3390\/nano10112304"},{"key":"3331_CR41","doi-asserted-by":"publisher","first-page":"113622","DOI":"10.1016\/j.jconrel.2025.113622","volume":"382","author":"L Xiong","year":"2025","unstructured":"Xiong L, Chen S, Li S, He D, Wang Y, Zhang Q, et al. ATP-responsive tumor targeted lipid nanoparticle for enhanced siRNA delivery and improved treatment efficacy in melanoma. J Control Release. 2025;382:113622.","journal-title":"J Control Release"},{"issue":"31","key":"3331_CR42","doi-asserted-by":"publisher","first-page":"6411","DOI":"10.2174\/0929867327666201022122131","volume":"28","author":"L Lu","year":"2021","unstructured":"Lu L, Zhang Q, Wang Z, Gao L, Shen J. Peptide-Modified Nanoparticles for Tumor Targeting and Molecular Imaging. Curr Med Chem. 2021;28(31):6411\u201336.","journal-title":"Curr Med Chem"},{"issue":"7","key":"3331_CR43","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1038\/s41401-020-0400-z","volume":"41","author":"J Gao","year":"2020","unstructured":"Gao J, Wang W-q, Pei Q, Lord MS, Yu H-j. Engineering nanomedicines through boosting immunogenic cell death for improved cancer immunotherapy. Acta Pharmacol Sin. 2020;41(7):986\u201394.","journal-title":"Acta Pharmacol Sin"},{"issue":"1","key":"3331_CR44","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1186\/s12943-025-02382-y","volume":"24","author":"KM Au","year":"2025","unstructured":"Au KM, Li S, Zhang T, Wang AZ. Biologically targeted dual adaptive and innate nano-Immunotherapy for clear cell renal cell carcinoma treatment. Mol Cancer. 2025;24(1):181.","journal-title":"Mol Cancer"},{"key":"3331_CR45","doi-asserted-by":"crossref","unstructured":"Dai Q, Cao B, Zhao S, Zhang A. Synergetic Thermal Therapy for Cancer: State-of-the-Art and the Future.Bioengineering 2022;9(9):474.","DOI":"10.3390\/bioengineering9090474"},{"key":"3331_CR46","doi-asserted-by":"crossref","unstructured":"Luo J-Q, Huang Y-C, Zhang J-Y, Tong Q-S, Batool A, Duan Y et al. Tumor pH-triggered PEG detachable nanoparticles for TLR7\/8 agonist del ivery to improve cancer immunotherapy. Biomater Sci. 2025;13(10):2794\u2013805.","DOI":"10.1039\/D5BM00243E"},{"issue":"18","key":"3331_CR47","doi-asserted-by":"publisher","first-page":"eaaz6579","DOI":"10.1126\/sciadv.aaz6579","volume":"6","author":"MA Shields CWt, Evans","year":"2020","unstructured":"Shields CWt, Evans MA, Wang LL, Baugh N, Iyer S, Wu D, et al. Cellular backpacks for macrophage immunotherapy. Sci Adv. 2020;6(18):eaaz6579.","journal-title":"Sci Adv"},{"issue":"7","key":"3331_CR48","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1038\/s41401-020-0448-9","volume":"41","author":"Q Sun","year":"2020","unstructured":"Sun Q, Bai X, Sofias AM, van der Meel R, Ruiz-Hernandez E, Storm G, et al. Cancer nanomedicine meets immunotherapy: opportunities and challenges. Acta Pharmacol Sin. 2020;41(7):954\u20138.","journal-title":"Acta Pharmacol Sin"},{"issue":"6","key":"3331_CR49","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1038\/s41581-024-00819-z","volume":"20","author":"Y Huang","year":"2024","unstructured":"Huang Y, Ning X, Ahrari S, Cai Q, Rajora N, Saxena R, et al. Physiological principles underlying the kidney targeting of renal nanomedicines. Nat Rev Nephrol. 2024;20(6):354\u201370.","journal-title":"Nat Rev Nephrol"},{"issue":"10","key":"3331_CR50","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1038\/nbt1340","volume":"25","author":"HS Choi","year":"2007","unstructured":"Choi HS, Liu W, Misra P, Tanaka E, Zimmer JP, Itty Ipe B, et al. Renal clearance of quantum dots. Nat Biotechnol. 2007;25(10):1165\u201370.","journal-title":"Nat Biotechnol"},{"issue":"1","key":"3331_CR51","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1080\/10717544.2020.1809559","volume":"27","author":"H Lan","year":"2020","unstructured":"Lan H, Zhang W, Jin K, Liu Y, Wang Z. Modulating barriers of tumor microenvironment through nanocarrier systems for improved cancer immunotherapy: a review of current status and future perspective. Drug Deliv. 2020;27(1):1248\u201362.","journal-title":"Drug Deliv"},{"key":"3331_CR52","doi-asserted-by":"crossref","unstructured":"D\u00e9zsi L, M\u00e9sz\u00e1ros T, \u0150rfi E, F\u00fcl\u00f6p TG, Hennies M, Rosivall L et al. Complement Activation-Related Pathophysiological Changes in Anesthetized Rats: Activator-Dependent Variations of Symptoms and Mediators of Pseudoallergy. Molecules. 2019;24(18):2418.","DOI":"10.3390\/molecules24183283"},{"key":"3331_CR53","doi-asserted-by":"publisher","first-page":"81","DOI":"10.2147\/IJN.S230879","volume":"15","author":"Z Yu","year":"2020","unstructured":"Yu Z, Wang Y, Xu D, Zhu L, Hu M, Liu Q, et al. G250 Antigen-Targeting Drug-Loaded Nanobubbles Combined with Ultrasound Targeted Nanobubble Destruction: A Potential Novel Treatment for Renal Cell Carcinoma. Int J Nanomed. 2020;15:81\u201395.","journal-title":"Int J Nanomed"},{"issue":"10","key":"3331_CR54","doi-asserted-by":"publisher","first-page":"8966","DOI":"10.1021\/acsnano.2c08240","volume":"17","author":"JQ Luo","year":"2023","unstructured":"Luo JQ, Liu R, Chen FM, Zhang JY, Zheng SJ, Shao D, et al. Nanoparticle-Mediated CD47-SIRP\u03b1 Blockade and Calreticulin Exposure for Improved Cancer Chemo-Immunotherapy. ACS Nano. 2023;17(10):8966\u201379.","journal-title":"ACS Nano"},{"issue":"16","key":"3331_CR55","doi-asserted-by":"publisher","first-page":"e2500141","DOI":"10.1002\/adhm.202500141","volume":"14","author":"Y Du","year":"2025","unstructured":"Du Y, Mai Y, Liu Z, Lin G, Luo S, Guo C, et al. Synergistic Provoking of Pyroptosis and STING Pathway by Multifunctional Manganese-Polydopamine Nano-Immunomodulator for Enhanced Renal Cell Carcinoma Immunotherapy. Adv Healthc Mater. 2025;14(16):e2500141.","journal-title":"Adv Healthc Mater"},{"issue":"1","key":"3331_CR56","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/s41698-024-00522-z","volume":"8","author":"S Wang","year":"2024","unstructured":"Wang S, Wang J, Chen Z, Luo J, Guo W, Sun L, et al. Targeting M2-like tumor-associated macrophages is a potential therapeutic approach to overcome antitumor drug resistance. NPJ Precis Oncol. 2024;8(1):31.","journal-title":"NPJ Precis Oncol"},{"issue":"12","key":"3331_CR57","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1038\/s41578-021-00385-x","volume":"6","author":"TI Janjua","year":"2021","unstructured":"Janjua TI, Cao Y, Yu C, Popat A. Clinical translation of silica nanoparticles. Nat Reviews Mater. 2021;6(12):1072\u20134.","journal-title":"Nat Reviews Mater"},{"issue":"1","key":"3331_CR58","first-page":"44","volume":"15","author":"Q Zhang","year":"2023","unstructured":"Zhang Q, Kuang G, Li W, Wang J, Ren H, Zhao Y. Stimuli-Responsive Gene Delivery Nanocarriers for Cancer Therapy. Nanomicro Lett. 2023;15(1):44.","journal-title":"Nanomicro Lett"},{"issue":"4","key":"3331_CR59","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/s41570-021-00251-y","volume":"5","author":"AR Chandrasekaran","year":"2021","unstructured":"Chandrasekaran AR. Nuclease resistance of DNA nanostructures. Nat Rev Chem. 2021;5(4):225\u201339.","journal-title":"Nat Rev Chem"},{"issue":"12","key":"3331_CR60","doi-asserted-by":"publisher","first-page":"e2006484","DOI":"10.1002\/smll.202006484","volume":"17","author":"F Oroojalian","year":"2021","unstructured":"Oroojalian F, Beygi M, Baradaran B, Mokhtarzadeh A, Shahbazi MA. Immune Cell Membrane-Coated Biomimetic Nanoparticles for Targeted Cancer Therapy. Small. 2021;17(12):e2006484.","journal-title":"Small"},{"issue":"4","key":"3331_CR61","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1039\/C8CS00457A","volume":"48","author":"J Wu","year":"2019","unstructured":"Wu J, Wang X, Wang Q, Lou Z, Li S, Zhu Y, et al. Nanomaterials with enzyme-like characteristics (nanozymes): next-generation artificial enzymes (II). Chem Soc Rev. 2019;48(4):1004\u201376.","journal-title":"Chem Soc Rev"},{"key":"3331_CR62","doi-asserted-by":"crossref","unstructured":"Kandasamy G, Maity D. Multifunctional theranostic nanoparticles for biomedical cancer treatm ents - A comprehensive review. Mater Sci Eng C. 2021;127:112199.","DOI":"10.1016\/j.msec.2021.112199"},{"issue":"Pt A","key":"3331_CR63","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.addr.2015.11.015","volume":"99","author":"M Swierczewska","year":"2016","unstructured":"Swierczewska M, Han HS, Kim K, Park JH, Lee S. Polysaccharide-based nanoparticles for theranostic nanomedicine. Adv Drug Deliv Rev. 2016;99(Pt A):70\u201384.","journal-title":"Adv Drug Deliv Rev"},{"key":"3331_CR64","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.jconrel.2020.02.008","volume":"321","author":"H Kinoh","year":"2020","unstructured":"Kinoh H, Shibasaki H, Liu X, Yamasoba T, Cabral H, Kataoka K. Nanomedicines blocking adaptive signals in cancer cells overcome tumor TKI resistance. J Control Release. 2020;321:132\u201344.","journal-title":"J Control Release"},{"issue":"2","key":"3331_CR65","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/s41565-021-01018-8","volume":"17","author":"H Zhang","year":"2022","unstructured":"Zhang H, Goh NS, Wang JW, Pinals RL, Gonz\u00e1lez-Grand\u00edo E, Demirer GS, et al. Nanoparticle cellular internalization is not required for RNA delivery to mature plant leaves. Nat Nanotechnol. 2022;17(2):197\u2013205.","journal-title":"Nat Nanotechnol"},{"issue":"32","key":"3331_CR66","doi-asserted-by":"publisher","first-page":"e2402973","DOI":"10.1002\/adhm.202402973","volume":"13","author":"Y Zhu","year":"2024","unstructured":"Zhu Y, Li Y, Li X, Yu Y, Zhang L, Zhang H, et al. Targeting Hypoxia and Autophagy Inhibition via Delivering Sonodynamic Nanoparticles With HIF-2\u03b1 Inhibitor for Enhancing Immunotherapy in Renal Cell Carcinoma. Adv Healthc Mater. 2024;13(32):e2402973.","journal-title":"Adv Healthc Mater"},{"issue":"20","key":"3331_CR67","doi-asserted-by":"publisher","first-page":"29291","DOI":"10.1021\/acsami.5c03559","volume":"17","author":"M Wu","year":"2025","unstructured":"Wu M, Zhao K, Tao X, Du L, Chen W, Guo H, et al. Biomimetic Copper Nanozyme Reprograms Cold Tumor via Cuproptosis-Pyroptosis Crosstalk for Potent Renal Carcinoma Immunotherapy. ACS Appl Mater Interfaces. 2025;17(20):29291\u2013304.","journal-title":"ACS Appl Mater Interfaces"},{"key":"3331_CR68","doi-asserted-by":"crossref","unstructured":"Du Y, Mai Y, Liu Z, Lin G, Luo S, Guo C et al. Synergistic Provoking of Pyroptosis and STING Pathway by Multifunction al Manganese-Polydopamine Nano-Immunomodulator for Enhanced Renal Cell Carcinoma Immunotherapy. Adv Healthc Mater. 2025;14(16):e2500141.","DOI":"10.1002\/adhm.202500141"},{"key":"3331_CR69","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.biomaterials.2018.08.053","volume":"183","author":"HO Alsaab","year":"2018","unstructured":"Alsaab HO, Sau S, Alzhrani RM, Cheriyan VT, Polin LA, Vaishampayan U, et al. Tumor hypoxia directed multimodal nanotherapy for overcoming drug resistance in renal cell carcinoma and reprogramming macrophages. Biomaterials. 2018;183:280\u201394.","journal-title":"Biomaterials"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-026-03331-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-026-03331-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-026-03331-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T03:46:47Z","timestamp":1785124007000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-026-03331-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,3]]},"references-count":69,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["3331"],"URL":"https:\/\/doi.org\/10.1007\/s12032-026-03331-5","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,3]]},"assertion":[{"value":"24 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors have agreed to the publication of this manuscript.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"212"}}